Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 7/20 | 0.70 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.70 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.70 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.70 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.70 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.70 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.70 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.70 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.70 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.70 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.70 |
| ▸ | NAAA | Q02083 | 1/20 | 0.70 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.58 |
| ▸ | NAMPT | P43490 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3863086 | 1.00 | HDAC1 (0.70) | HDAC1HDAC2HDAC8HDAC6HDAC3 | |
| SCHEMBL4426060 | 1.00 | HDAC1 (0.70) | HDAC1HDAC2HDAC8HDAC6HDAC3 | |
| SCHEMBL13709041 | 1.00 | HDAC1 (0.70) | HDAC1HDAC2HDAC8HDAC6HDAC3 | |
| SCHEMBL8366892 | 1.00 | HDAC1 (0.70) | HDAC1HDAC2HDAC8HDAC6HDAC3 | |
| Hydrochloric Acid SCHEMBL4326160 | 0.98 | HDAC1 (0.68) | HDAC1HDAC2HDAC8HDAC6HDAC3 | |
| Hydrochloric Acid SCHEMBL5969581 | 0.98 | HDAC1 (0.68) | HDAC1HDAC2HDAC8HDAC6HDAC3 | |
| SCHEMBL5855204 | 0.98 | HDAC1 (0.67) | HDAC1HDAC2HDAC8HDAC6HDAC3 | |
| SCHEMBL1467538 | 0.93 | NPC1 (0.66) | HDAC1HDAC2HDAC8HDAC6HDAC3 | |
| SCHEMBL15065078 | 0.92 | GRIN1 (0.61) | HDAC1HDAC2HDAC8HDAC6HDAC3 | |
| SCHEMBL19874469 | 0.91 | NPC1 (0.64) | HDAC1HDAC2HDAC8HDAC6HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100562511-C | 2-aryl-acetic acids, their derivative and contain their pharmaceutical composition | DOMPE SPA (IT) | 2009-11-25 | — | — | CN | claimed |
| US-12227634-B2 | Fiber sheet and method for producing same | KAO CORPORATION (JP) | 2025-02-18 | — | — | US | disclosed |
| CN-118348134-A | Reagents and methods for screening MPS I, II, IIIA, IIIB, IVA, VI and VII | 华盛顿大学商业中心 | 2024-07-16 | — | — | CN | disclosed |
| CN-112986429-B | Reagents and methods for screening MPS I, II, IIIA, IIIB, IVA, VI and VII | 华盛顿大学商业中心 | 2024-03-29 | — | — | CN | disclosed |
| US-20230203082-A1 | REAGENTS AND METHODS FOR SCREENING MPS I, II, IIIA, IIIB, IVA, VI, AND VII | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230203082-A1 | REAGENTS AND METHODS FOR SCREENING MPS I, II, IIIA, IIIB, IVA, VI, AND VII | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230203082-A1 | REAGENTS AND METHODS FOR SCREENING MPS I, II, IIIA, IIIB, IVA, VI, AND VII | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2023-06-29 | — | — | US | disclosed |
| US-11618764-B2 | Reagents and methods for screening MPS I, II, IIIA, IIIB, IVA, VI, and VII | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2023-04-04 | — | — | US | disclosed |
| EP-4019527-A1 | REAGENTS AND METHODS FOR SCREENING MPS II | University Of Washington Through Its Center For Commercialization (US) | 2022-06-29 | — | — | EP | disclosed |
| EP-4019527-A1 | REAGENTS AND METHODS FOR SCREENING MPS II | University Of Washington Through Its Center For Commercialization (US) | 2022-06-29 | — | — | EP | disclosed |
| EP-1187613-B9 | AMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2006-10-25 | — | — | EP | disclosed |
| EP-1187613-B1 | AMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20040229897-A1 | Amide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-11-18 | — | — | US | disclosed |
| US-6756382-B2 | SECONDARY AMIDES SUCH AS N-(4-(4-AMINO-2-(2-METHOXYETHYL)-1H-IMIDAZO(4,5-C)QUINOLIN-1-YL)BUTYL)-1 -METHYL-5-OXO-2-PYRIDIN-3-YLPYRROLIDINE-3-CARBOXAMIDE; BIOSYNTHESIS OF CYTOKINES; PROPYLAXIS OF VIRAL DISEASES; IMMUNOLOGY MODULATORS | 3M INNOVATIVE PROPERTIES COMPANY | 2004-06-29 | — | — | US | disclosed |
| US-20030144283-A1 | Amide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-07-31 | — | — | US | disclosed |
| US-6451810-B1 | AID IN CYTOKINE BIOSYNTHESIS | 3M INNOVATIVE PROPERTIES COMPANY | 2002-09-17 | — | — | US | disclosed |
| EP-1187613-A4 | AMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2002-07-24 | — | — | EP | disclosed |
| EP-1187613-A1 | AMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2002-03-20 | — | — | EP | disclosed |
| WO-2000076505-A1 | AMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
| EP-0339976-B1 | Anti-tumour agents | ICI PLC (GB) | 1994-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229897-A1 | Amide substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | HDAC1 89/4885HDAC2 119/4885HDAC8 197/4885 |
| US-11618764-B2 | Reagents and methods for screening MPS I, II, IIIA, IIIB, IVA, VI, and VII | GAA, MAN2B1, CLN6 | HDAC1 3253/4885HDAC2 2810/4885HDAC8 2396/4885 |
| US-20230203082-A1 | REAGENTS AND METHODS FOR SCREENING MPS I, II, IIIA, IIIB, IVA, VI, AND VII | GAA, MAN2B1, CLN6 | HDAC1 3253/4885HDAC2 2810/4885HDAC8 2396/4885 |
| US-20030144283-A1 | Amide substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | HDAC1 89/4885HDAC2 119/4885HDAC8 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.